Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy

Cancer Medicine
Yoshimi MizunoJunya Kuroda

Abstract

Diffuse large B-cell lymphoma (DLBCL), which is the most prevalent disease subtype of non-Hodgkin lymphoma, is highly heterogeneous in terms of cytogenetic and molecular features. This study retrospectively investigated the clinical impact of G-banding-defined chromosomal abnormality on treatment outcomes of DLBCL in the era of rituximab-containing immunochemotherapy. Of 181 patients who were diagnosed with DLBCL and treated with R-CHOP or an R-CHOP-like regimen between January 2006 and April 2014, metaphase spreads were evaluable for G-banding in 120. In these 120 patients, 40 were found to harbor a single chromosomal aberration type; 63 showed chromosomal abnormality variations (CAVs), which are defined by the presence of different types of chromosomal abnormalities in G-banding, including 19 with two CAVs and 44 with ≥3 CAVs; and 17 had normal karyotypes. No specific chromosomal break point or numerical abnormality was associated with overall survival (OS) or progression-free survival (PFS), but the presence of ≥3 CAVs was significantly associated with inferior OS rates (hazard ratio (HR): 2.222, 95% confidence interval (CI): 1.056-4.677, P = 0.031) and tended to be associated with shorter PFS (HR: 1.796, 95% CI: 0.965-3.344...Continue Reading

References

May 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D Rowley
Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R Dalla-FaveraC M Croce
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Jun 9, 2006·The New England Journal of Medicine·Sandeep S DaveUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Jan 30, 2008·The Lancet Oncology·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Sep 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Georg LenzLouis M Staudt
Dec 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Samuel F BakhoumDuane A Compton
Apr 3, 2012·The Journal of Clinical Investigation·Samuel F Bakhoum, Duane A Compton
Aug 21, 2013·The Journal of Experimental Medicine·Noel F C C de MirandaQiang Pan-Hammarström
Aug 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grzegorz S NowakowskiThomas E Witzig
Dec 5, 2015·Current Treatment Options in Oncology·Kieron Dunleavy
Dec 3, 2016·Methods in Molecular Biology·Huifang Huang, Jiadi Chen

❮ Previous
Next ❯

Citations

Jul 4, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ni SunXiao-Ji Lin

❮ Previous
Next ❯

Methods Mentioned

BETA
chromosomal aberration

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.